Wedbush Maintains Outperform on Generation Bio, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has maintained an Outperform rating on Generation Bio (NASDAQ:GBIO), but lowered the price target from $11 to $9.

November 10, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst has maintained an Outperform rating on Generation Bio but lowered the price target from $11 to $9.
The news is directly about Generation Bio. The Outperform rating suggests that the analyst expects the stock to do better than the market average, which is positive. However, the lowering of the price target from $11 to $9 indicates a reduced future valuation, which could have a negative impact. The net effect is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100